Investing.com - Verona Pharma (NASDAQ:VRNA) ADR reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Verona Pharma ADR announced earnings per share of $-0.05 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.5532 on revenue of $0.00.
Verona Pharma ADR shares are down 18.01% from the beginning of the year, still down 40.54% from its 52 week high of $9.27 set on March 3, 2021. They are under-performing the Nasdaq which is down 12.1% from the start of the year.
Verona Pharma ADR follows other major Healthcare sector earnings this month
Verona Pharma ADR's report follows an earnings matched by Roche Holding ADR on February 3, who reported EPS of $1.29 on revenue of $17.54B, compared to forecasts EPS of $1.29 on revenue of $17.1B.
Pfizer had beat expectations on February 8 with fourth quarter EPS of $1.08 on revenue of $23.84B, compared to forecast for EPS of $0.8742 on revenue of $24.16B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar